Formal UK Medical Devices Legislation Expected In Spring

The Queen’s speech last month signaled new legislation for medical devices after the UK leaves the umbrella of EU legislation, following the December election result. The bill is expected to enter its second reading in March 2020.

Parliament

The Queen’s speech of 19 December, and background information published on 20 December, came just a week after the election result that was effectively the pro-Brexit vindication that UK prime minister Boris Johnson saw as long-overdue after the June 2016 referendum.

It effectively brought to an end the wrangling over the merits of UK membership of the EU. (Also see "UK Medtechs Must Face Up To Brexit Certainty After Election...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.